Paliperidone

證據等級: L5

預測適應症: 10 個

Paliperidone: From Schizophrenia to Retinal Dystrophy with or without Extraocular Anomalies

One-Sentence Summary

Paliperidone is a D2/5-HT2A receptor antagonist used clinically to treat schizophrenia. The TxGNN model's top-ranked prediction is Retinal Dystrophy with or without Extraocular Anomalies, but this candidate has 0 clinical trials and 15 publications, none of which mention paliperidone or its pharmacology — the drug's own evidence pack flags this as a likely embedding-similarity false positive rather than a genuine mechanistic signal.

Quick Overview

Item	Content
Original Indication	Not documented in BfArM/regulatory data (product not marketed in Germany); known clinical use is schizophrenia, inferred from mechanism notes elsewhere in this evidence pack
Predicted New Indication	Retinal dystrophy with or without extraocular anomalies
TxGNN Prediction Score	99.92%
Evidence Level	L5
Germany Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

It is not. Detailed MOA data is marked as a data gap in the drug record, but the evidence pack's own rationale field (drawn from the rank-10 candidate) confirms paliperidone is a D2/5-HT2A receptor antagonist — a centrally acting antipsychotic mechanism with no known connection to retinal developmental genes or ophthalmic structural pathways.

The retinal dystrophy prediction ranks #1329 out of the model's full output and carries a very high raw similarity score, but score magnitude alone does not establish biological plausibility. The 15 supporting publications retrieved for this candidate cover unrelated ophthalmology topics — orbital infections, diplopia, congenital ptosis, cryptophthalmia, congenital cranial dysinnervation disorders — and none reference paliperidone, antipsychotics, or D2/5-HT2A signaling. The evidence pack itself characterizes this as a probable false positive caused by embedding-space similarity rather than a real mechanistic link.

Candidates ranked #2–#9 (X-linked myopia, hydranencephaly, congenital disorders of glycosylation, Charcot-Marie-Tooth disease type 1G, etc.) share the same pattern: high TxGNN scores, zero supporting trials or literature, and no plausible mechanistic rationale given the drug's known pharmacology. By contrast, the #10-ranked candidate — treatment-refractory schizophrenia — is mechanistically coherent (it sits within paliperidone's known therapeutic class) and is the only candidate in this pack backed by real clinical trial and literature evidence (see Conclusion).

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
9416661	1997	Review/Case	Semin Ultrasound CT MR	Orbital infections secondary to sinusitis; not related to paliperidone or retinal dystrophy pathophysiology
20127583	2010	Review	Semin Neurol	Diagnostic approach to diplopia; unrelated to drug mechanism
38321238	2024	Review	Pediatr Radiol	Imaging of pediatric congenital ocular pathologies; no drug relevance
38249493	2023	Review	Taiwan J Ophthalmol	Congenital lens shape anomalies; no drug relevance
22241537	2012	Review	Klin Monbl Augenheilkd	Congenital ptosis pathophysiology; no drug relevance
109006	1979	Case Report	Am J Ophthalmol	Unilateral cryptophthalmia case series; no drug relevance
7035111	1981	Review	Doc Ophthalmol	Wagner-Stickler syndrome vitreoretinal degeneration; no drug relevance
33806565	2021	Cohort	Int J Mol Sci	Optic nerve/retinal findings in congenital fibrosis of extraocular muscles; no drug relevance
30196776	2018	Review	J Binocul Vis Ocul Motil	Congenital cranial dysinnervation disorders overview; no drug relevance
24932988	2014	Review	Am J Ophthalmol	Maculopathy from cavitary optic disc anomalies; no drug relevance

None of the retrieved literature mentions paliperidone, antipsychotics, or dopaminergic/serotonergic mechanisms — confirming these are topical co-retrieval matches rather than mechanistic evidence.

Germany Market Information

Paliperidone is not marketed in Germany; no BfArM authorizations are on record in this evidence pack.

Safety Considerations

Please refer to the package insert for safety information.

Note: TFDA/BfArM label data (warnings, contraindications) is flagged as a Blocking data gap in this evidence pack (DG001) and could not be retrieved — this must be resolved before any S1 safety screening can proceed, regardless of which indication is pursued.

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked candidate (retinal dystrophy with or without extraocular anomalies) has no clinical trials, no relevant literature, and no plausible mechanistic link to paliperidone's D2/5-HT2A antagonism — the evidence pack itself identifies it as a likely false positive from embedding similarity. The same applies to candidates ranked #2–#9.

To proceed, the following is needed:

Resolve the Blocking data gap: obtain TFDA/BfArM label (warnings, contraindications) before any safety screening
Obtain confirmed MOA and original indication documentation for paliperidone (currently marked as data gaps)
If pursuing repurposing work on this drug, redirect evaluation toward rank #10 (treatment-refractory schizophrenia), which is the only candidate with real supporting evidence (L2, 4 clinical trials including one completed Phase 4 study, 2 literature reviews) — note this represents an indication-extension within paliperidone's existing therapeutic class rather than a novel repurposing signal, and would still require head-to-head comparative data against clozapine (the current standard for treatment-refractory schizophrenia) before advancing past S2
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.